Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School, outlines what needs to happen next in his research developing a type 1 diabetes (T1D) vaccine.
Next steps in investigating a type 1 diabetes (T1D) vaccine include developing a better understanding of the effects of the vaccine in non-obese diabetic (NOD) mice and in human pancreases, said Aleksandar Kostic, PhD, an assistant professor of microbiology at Harvard Medical School.
Transcript:
What are the next steps for your research on a type 1 diabetes (T1D) vaccine?
So what we really want to do is now understand whether this is also happening in human T1D. We have had access to 2 or 3 individuals who had T1D and passed away and donated their organs to research. We were able to find in those individuals the presence of poly N-acetyl glucosamine (PNAG) in their pancreases. We've only had access to 1 healthy control pancreas where we were not able to find PNAG. Getting access to these specimens is quite challenging. These things are so precious. But we're working with [the Network of Pancreatic Organ Donors with Diabetes] nPOD now, as well as some other organizations, to try to get a much larger sample and see whether this is, in fact, a statistically significant effect and that whether in humans this is also observed.
The other piece of it that we're trying to understand in much better detail is within the pancreases of NOD mice. What is the general time frame of microbial translocation or microbial fragment translocation into these mice? And how does vaccination with PNAG impact the time frame and maybe the abundance of these microbial fragments in the pancreas to help us better understand how this is happening? Generally, we're trying to build a more comprehensive picture of the immune cells that are infiltrating into the beta cells and in specifically the vaccination, which immune cells now are much less prevalent in beta cells and might be responsible for the protection.
Study Shows Higher Infection Risk in Patients With T1D in Primary, Secondary Care
November 22nd 2023Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
High BMI Associated With Increased Risk of Type 1 Diabetes
November 10th 2023In a systematic and meta-analysis review of cohort studies that featured nearly 1.7 million individuals, study authors concluded that there is an association between high body mass index (BMI) and an increased risk of incident type 1 diabetes.
Read More